Contact Us

Baycol
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date you started taking this drug:

Date you stopped taking this drug:

What additional medications were you taking at the time?

Was Gemfibrozil (Lopid) taken while taking Baycol?

Has Rhabdomyolysis been diagnosed?

Have any of the following side effects occurred?







Please further describe side effects:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Bayer Faces More Suits

Jan 16, 2003 | FT.com Bayer, the German pharmaceutical and chemical group, said on Wednesday the number of suits it was facing over Baycol, the cholesterol-lowering agent it was forced to withdraw from the market in 2001, had risen to 7,400 from an earlier 5,700 in November.

That number is far above earlier estimates. Bayer said it had settled 400 suits out of court.

Investors are worried that Bayer could face an unforeseeably high financial burden if the claimants win the lawsuits.

Bayer said it expects the first case to be heard in the spring.

Bayer has repeatedly said that it sees no reason to make special provision for the lawsuits.

It argues its insurance will pay for potential claims.

The withdrawal of Baycol, sold as Lipobay in the US, has left the German conglomerate vulnerable and in urgent need of a pharmaceuticals partner to boost its drugs pipeline.

In 2001 alone, the withdrawal of Baycol is estimated to have lowered the group's operating profit by about €800m ($845m). Since then, Bayer's share price has halved.

Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo